Medtronic touts study of accuracy, cost effectiveness of capnography monitors

Medtronic (NYSE:MDT) today presented data from 2 clinical studies of its  capnography patient monitoring systems, touting their accuracy and cost-effectiveness. Data from the studies was presented at the Anesthesiology 2015 annual meeting in San Diego this week. “The findings presented today demonstrate the clinical benefits and potential cost savings capnography can provide across a broad spectrum of patients. These studies underscore Medtronic’s commitment to reducing the growing burden of respiratory compromise across clinical settings to improve the health and care of patients,” Medtronic minimally invasive therapies group medical chief Dr. Michael Tarnoff said in a press release. The Fridley, Minn.-based medical giant said a 163-patient prospective observational study of its IPI system in post anesthesia care units found it can help predict respiratory adverse events more effectively than pulse oximetry alone. The study looked at patients with high-risk for hypoventilation following general surgery, defined as having a body-mass index of more than 28 or over 75 years old. Patients were monitored with Medtronic’s Capnostream 20 patient monitor, which measured pulse oximetery, pulse rate, respiratory rate and end-tidal carbon dioxide for the IPI, the company reported. Data from the study indicated a lower IPI in the 7% of patients who experienced a respiratory adverse event compared to non RAE-patients, and that sensitivity and specificity of IPI ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Diagnostics Medtronic Source Type: news